Chemical conjugation of fatty acids to antibodies generates lipid-modified molecules which have found use in the targeting of liposome-mediated drug delivery and in liposome-based immunoassays. Alternatively, bacterial expression of antibodies as single-chain FV fragments fused to lipoprotein signal peptide and N-terminal sequence leads to in vivo enzymatic addition of a single glycerolipid group at the N-terminus of the molecule. This lipid-modification converts the antibody from a soluble protein into a functional membrane-bound molecule. These biosynthetically lipid-tagged antibodies may prove useful for immobilization of antibodies to membranes in various biotechnological applications.
No takes yet. Share an insight, caveat, or question.
Keinänen et al. (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: